Analysis of 20 Years of Legislative Trends to Predict Future Investment and Access to Orphan Drugs

Medrano J¹, Shah A¹, Scinicariello N¹, Neubert S¹

¹Costello Medical, Boston, MA, US

Objective

To identify legislative trends in the United States (US) that may influence investment and access to orphan drugs (ODs) and policies that can be impacted by changes in federal spending by examining the frequency, volume, and topics of rare disease (RD)/OD-related laws passed over the last 20 years.

Background

- Government legislation profoundly shapes the US pharmaceutical industry's investment, pricing, and market access strategies for RDs and ODs. The Orphan Drug Act boosted OD availability from 38 to over 600 since its enactment in 1983,¹ enhancing market availability. The Inflation Reduction Act has resulted in many companies rethinking investments and clinical development pipelines for multi-indication drugs as the FDA have approved roughly one-quarter of ODs from 2003 to 2022 for at least 1 follow-on indication.^{2,3}
- Given the number of recent changes to federal spending, it is important to understand what legislation exists surrounding RDs, as knowledge of current legislation can help stakeholders mitigate risks associated with unpredictable policy shifts.

Methods

- An overview of the methodology is presented in Figure 1
- On 3 January 2025, targeted searches of the Library of Congress were conducted to identify RD/OD-related legislation passed since 3 January 2005 searching for keywords in bill titles, summaries, and text.⁴
- Information on the presiding president, status, introduction and enactment dates, and relevance to RD community needs for each bill identified in searches were extracted into a predefined grid and qualitatively analyzed.
- RD/OD-related bills enacted as law were then categorized based on a previous framework used to review policies for rare diseases in the context of key patient needs across 11 countries.⁵ As described by Dharssi (2017), the following elements were evaluated for each bill: access to treatment, diagnosis programs, coordination of care, research, and patient engagement.

Results

RD/OD-Related Bills Enacted as Law

- Of the 278 RD/OD-related bills introduced to Congress since 2005, 19 (7%) became law (**Figure 2**).
- Of the 19 bills that were enacted, 13/19 (68%) were introduced from 2005–2015, compared to 6/19 (32%) from 2016-2025.
- 12/19 (63%) of RD/OD-related legislation focused on promoting RD/OD research through funding, awards for clinical trial coordination, and patient recruitment incentives.
- 9/19 (47%) RD/OD-related laws focused on patient engagement, 6/19 (32%) on coordination of care, 5/19 (26%) on diagnosis programs, and 4/19 (21%) on expanding access to ODs.

RD/OD-Related Legislation by Presidential Term


- The highest number of laws (6/19 [32%]) were passed during President Barack Obama's first term (111th and 112th Congresses) (**Figure 3**).
- 11/19 (58%) of RD/OD-related laws were passed across President Barack Obama's two terms (111th–114th Congresses).
- The lowest number of laws (2/19 [11%] each) were passed during both President Donald Trump's first term (115th and 116th Congresses) and President George W. Bush's second term (109th and 110th Congresses).

Conclusion

Over the past 20 years, the majority of RD/OD-related legislation has been focused on promoting RD/OD research, with fewer RD/OD-related bills enacted into law from 2016 to 2025 compared with 2005–2015. While this focus may boost future OD availability, recent cuts in US government spending raise concerns about sustained policy attention. These changes in the federal budget highlight the need for increased public awareness and advocacy to ensure RD/OD issues remain a legislative priority amidst a decrease in federal spending.

FIGURE 1

Overview of methodology



References: 1PharmaLive.com. Recognizing the 40th Anniversary of the Orphan Drug Act. Accessed at: https://www.pharmalive.com/recognizing-the-40th-anniversary-of-the-orphan-drug-act-the-rare-disease-company-coalition-calls-on-policymakers-to-renew-commitment-to-advancing-innovation-for-rare-disease-patients/ [Last accessed 1 April 2025]; ²The Wall Street Journal. Big Pharma Cuts R&D, Sending Shudders Through Industry. Accessed at: https://www.congress.gov/browse [Last accessed 3 November 2024]; ³Chambers J.D. et al. JAMA Netw Open 2023;6:e2329006; ⁴Library of Congress. Accessed at: https://www.congress.gov/browse [Last accessed 3 November 2024]; ⁵Dharssi S. et al. Orphanet J Rare Dis 2017;12:63. Acknowledgements: The authors thank, Martina Tasende, Costello Medical, for graphic design assistance. We also thank Rachana Kilaru for their contributions.

FIGURE 2

Summary of RD/OD-related legislation enacted from 3 January 2005 to 3 January 2025


			RD/OD-Related Policy Categories				
			↓ (+) (+) (+) (+) (+) (+) (+) (+)	\bigcirc			sHo
ngress	Legislation Number	Legislation Name	Coordination of Care	Diagnosis Programs	Access to Treatment	Patient Engagement	Research
th 05–2006)	H.R. 6164	National Institutes of Health Reform Act of 2006	\bigotimes	\bigotimes	(\times)	(\times)	\bigcirc
th 07–2008)	H.R. 3580	Food and Drug Administration Amendments Act of 2007	\bigotimes	\bigcirc	\bigotimes	\bigcirc	\bigcirc
	H.R. 2997	Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010	\bigotimes	\bigotimes	\bigotimes	\bigotimes	\bigotimes
h	H.R. 3590	Patient Protection and Affordable Care Act	\bigcirc	\bigotimes	\bigotimes	\bigcirc	\bigcirc
09–2010)	H.R. 4872	Health Care and Education Reconciliation Act of 2010	\bigcirc	\bigotimes	\bigotimes	\bigcirc	\bigotimes
	S. 1674	Improving Access to Clinical Trials Act of 2009	\otimes	\bigotimes	\bigotimes	\bigcirc	\bigcirc
	H.R. 4994	Medicare and Medicaid Extenders Act of 2010	\bigcirc	\bigotimes	\bigcirc	\bigotimes	\bigotimes
th 11–2012)	S. 3187	Food and Drug Administration Safety and Innovation Act	\otimes	\bigcirc	\bigcirc	\bigcirc	\bigotimes
th	S. 252	PREEMIE Reauthorization Act	\bigcirc	\bigcirc	\bigotimes	\bigcirc	\bigcirc
13–2014)	H.R. 5771	Tax Increase Prevention Act of 2014	\otimes	\bigotimes	\bigotimes	\bigotimes	\bigcirc
^{,th})15–2016)	S. 139	Ensuring Access to Clinical Trials Act of 2015	\otimes	\bigotimes	\bigotimes	\bigcirc	\bigcirc
	S. 1878	Advancing Hope Act of 2016	\otimes	\bigcirc	\bigcirc	\bigotimes	\bigotimes
	H.R. 34	21st Century Cures Act	\otimes	\bigcirc	\bigcirc	\bigcirc	\bigcirc
th 17–2018)	H.R. 2430	An act to amend the Federal Food, Drug, and Cosmetic Act $^{\scriptscriptstyle \dagger}$	\bigotimes	\bigotimes	\bigotimes	\bigotimes	\bigcirc
th 19–2020)	H.R. 1839	Medicaid Services Investment and Accountability Act of 2019	\bigcirc	\bigotimes	\bigotimes	\bigcirc	\bigotimes
th)21–2022)	H.R. 5376	Inflation Reduction Act of 2022	\otimes	\bigotimes	\bigotimes	\bigotimes	\otimes
	H.R. 6833	Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023	\bigotimes	\bigotimes	(\times)	(\times)	\bigcirc
	H.R. 1437	Further Continuing Appropriations and Extensions Act, 2023	\bigotimes	\bigotimes	\bigotimes	\bigotimes	\bigcirc
	H.R. 2617	Consolidated Appropriations Act, 2023	\bigcirc	\bigotimes	\bigotimes	\bigotimes	\bigcirc

White/gray shading under RD/OD-Related Policy Categories corresponds to the grouping of the Congresses in the left-most column. A check mark indicates that the legislation includes RD/OD-related policy for the corresponding category, whereas an 'X' indicates that policy related to the corresponding category is not included in the legislation. [†]The bill's name in its entirety is 'An act to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription

HPR149



(2017 - 2020)



(2021 - 2024)

